Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.
Latest from Xu Hu
The acceleration of commercial health insurance was included in national development plans for 2026 released by the Chinese government in the recent “Two Sessions” policy meetings, and appears key for the next generation of innovative drugs to achieve domestic success.
China's government formally designated the biopharma sector as a newly emerging "pillar industry" in the recent “Two Sessions” meeting in Beijing, the repositioning implying it will be a high-priority industry for the next decade.
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
China has granted a world-first approval to a cAMP-biased GLP-1R agonist, Sciwind's ecnoglutide, for weight management, following convincing Phase III results.
Designation of more regulatory resources by China’s top drug regulator to the cell therapy sector appears key to the recent consecutive release of guidelines related to CAR-T products in the country.
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.